Every Form 4 that MAIA Biotechnology Inc. (MAIA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MAIA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MAIA filings page.
MAIA Biotechnology, Inc. (MAIA) director Ramiro Guerrero reported a series of open-market purchases of the company’s common stock. On August 26–28, 2026, he purchased a total of 133,790 shares in three transactions at per-share prices between $1.35 and $1.39, with no sales reported.
MAIA Biotechnology, Inc. (MAIA) director Ramiro Guerrero purchased common stock in an open-market or private transaction. On 2026-08-24, he bought 1,794 shares of MAIA common stock at a price of $1.33 per share, bringing his directly held position to 601,911 shares of common stock following the transaction.
MAIA Biotechnology, Inc. (MAIA) director Ramiro Guerrero reported purchasing common stock in an open market or private transaction. On 2026-08-20, he bought 11,899 shares at $1.37 per share, bringing his directly held position to 600,117 shares following the transaction. The filing indicates the Rule 10b5-1 checkbox was not selected.
MAIA Biotechnology, Inc. director Steven M. Chaouki reported a compensation-related grant of stock options. He received options covering 26,982 shares of common stock at an exercise price of $1.44 per share, granted on June 30, 2026 under the company’s 2021 Equity Incentive Plan.
The options vest 100% on the grant date and are exercisable beginning that date, with an expiration date of June 30, 2036. Following this grant, Chaouki holds 26,982 stock options directly.
MAIA Biotechnology director Ramiro Guerrero received a grant of stock options, acquiring rights to 26,355 shares of common stock. The options have an exercise price of $1.44 per share, vest 100% on the grant date of June 30, 2026, and are exercisable immediately through June 30, 2036.
MAIA Biotechnology director Louie Ngar Yee received a grant of stock options on common shares. The award covers 32,630 options with an exercise price of $1.44 per share, granted under the company’s 2021 Equity Incentive Plan. The options vest 100% on the grant date and are immediately exercisable, expiring on June 30, 2036. Following this grant, Louie Ngar Yee holds 32,630 derivative securities directly.
MAIA Biotechnology director Cristian Luput received a grant of stock options as equity compensation. He was awarded 27,610 stock options on the company’s common stock at an exercise price of $1.44 per share. The options vest 100% on the grant date and are immediately exercisable, giving him the right to buy up to 27,610 shares of common stock. Following this grant, his directly held stock option position reported in this filing totals 27,610 options, which remain outstanding until their stated expiration in 2036.
MAIA Biotechnology director Stan Smith reported a grant of stock options. On June 30, 2026, he was awarded 32,003 stock options under the company’s 2021 Equity Incentive Plan, each with an exercise price of $1.44 per share. The options vest 100% on the grant date and are immediately exercisable for up to 32,003 shares of common stock. Following this compensation-related award, he holds 32,003 options indirectly through The Stan V. Smith Trust Dated 1993.
MAIA Biotechnology director Theagene Jean-Manasse received a new stock option grant as equity compensation. The grant covers 26,355 stock options, each allowing the purchase of common stock at an exercise price of $1.44 per share. According to the disclosure, these options vest 100% on the grant date of June 30, 2026 and are exercisable beginning that same day. Following this award, the filing shows 26,355 derivative securities held, indicating this is a new option position rather than a sale or open-market purchase of shares.
MAIA Biotechnology, Inc. Chief Executive Officer and director Vitoc Vlad reported an open-market purchase of 72,700 shares of common stock. The shares were bought at a weighted average price of $1.3877 per share, across multiple trades priced between $1.3634 and $1.4150.
Following this purchase, Vlad directly holds 976,121 shares of MAIA common stock. The filing also notes an additional 210,100 shares of common stock beneficially owned by his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
MAIA Biotechnology director Stan Smith, through an indirect trust ownership, reported an open-market purchase of 75,000 shares of Common Stock of MAIA Biotechnology at a weighted average price of $1.336 per share. The filing states the shares were bought in multiple trades between $1.32 and $1.40.
After this transaction, an entity associated with Smith held 1,519,178 shares indirectly. Additional indirect holdings of 4,580 shares are shown in separate trust accounts for family members, where Smith disclaims beneficial ownership beyond his pecuniary interest.
MAIA Biotechnology, Inc. Chief Scientific Officer Sergei Gryaznov reported an open-market purchase of 2,000 shares of Common Stock on June 1, 2026 at a price of $1.345 per share. Following this transaction, he directly holds 46,511 shares of MAIA Biotechnology Common Stock.
MAIA Biotechnology, Inc. reported that Chief Executive Officer and 10% owner Vitoc Vlad received a grant of 800,000 stock options on May 29, 2026 under the company’s 2021 Equity Incentive Plan. These options allow him to buy common stock at an exercise price of $1.39 per share until May 29, 2036.
The grant is a compensation award rather than an open-market purchase. The options vest over four years, with 25% vesting on the first anniversary of the grant and the remaining 75% vesting monthly over the following 36 months, aligning his incentives with longer-term company performance.
MAIA Biotechnology, Inc. reported that Chief Scientific Officer Sergei Gryaznov received a grant of stock options covering 400,000 shares of common stock. These options have an exercise price of $1.39 per share and expire on May 29, 2036.
The grant was made under MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan. The options vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining options vesting monthly over the following 36 months.
MAIA Biotechnology, Inc. reported that Head of Finance Jeffrey C. Himmelreich received a grant of stock options covering 60,000 shares of common stock. The options have an exercise price of $1.39 per share and expire on May 29, 2036.
The award was granted under the company’s 2021 Equity Incentive Plan. The options vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining options vesting in equal monthly installments over the following 36 months.
MAIA Biotechnology CEO Vitoc Vlad received a grant of 800,000 stock options as equity compensation. The options give him the right to buy 800,000 shares of common stock at an exercise price of $1.28 per share and expire on April 10, 2036.
The grant was made under MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan. The options vest over four years, with 25% vesting on the first anniversary of the April 10, 2026 grant date and the remaining 75% vesting in equal monthly installments over the following 36 months. After this grant, Vlad holds 800,000 options directly, and the filing shows no open-market stock purchases or sales.
MAIA Biotechnology’s Chief Scientific Officer Sergei Gryaznov received a grant of 400,000 stock options to acquire common shares at an exercise price of $1.28 per share. These options were granted under MAIA Biotechnology, Inc.’s 2021 Equity Incentive Plan as part of equity-based compensation.
The options vest over four years, with 25% vesting on the first anniversary of the April 10, 2026 grant date and the remaining options vesting in equal monthly installments over the following 36 months. After this grant, Gryaznov holds 400,000 stock options directly, according to the filing.
MAIA Biotechnology, Inc. reported that its Head of Finance, Jeffrey C. Himmelreich, received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $1.28 per share and expire on April 10, 2036. They were granted under the company’s 2021 Equity Incentive Plan as a compensation award, not an open-market purchase. The options vest over four years, with 25% vesting on the first anniversary of the April 10, 2026 grant date and the remainder vesting monthly over the following 36 months, and represent Himmelreich’s full reported option position of 30,000 shares after this grant.
MAIA Biotechnology, Inc. director Steven M. Chaouki received a grant of stock options for 27,907 shares of common stock on March 31, 2026. The options carry an exercise price of $1.40 per share, vest 100% on the grant date, and are exercisable immediately through March 31, 2036.
MAIA Biotechnology director Ramiro Guerrero received a grant of stock options as equity compensation. He was awarded 27,258 stock options on March 31, 2026 with an exercise price of $1.40 per share, each option representing one share of common stock.
The options were granted under MAIA Biotechnology, Inc.’s 2021 Equity Incentive Plan, vest 100% on the grant date, and are exercisable beginning March 31, 2026. Following this grant, Guerrero holds 27,258 stock options directly, with the options scheduled to expire on March 31, 2036.
MAIA Biotechnology, Inc. director Louie Ngar Yee received a grant of stock options for 33,748 shares of common stock. The options were granted on March 31, 2026 at an exercise price of $1.40 per share, vest 100% on the grant date, and are immediately exercisable.
Following this grant, he holds 33,748 stock options directly, which are scheduled to expire on March 31, 2036.
MAIA Biotechnology, Inc. director Cristian Luput received a grant of stock options representing the right to acquire 28,556 shares of common stock. The options were granted on March 31, 2026, with an exercise price of $1.40 per share, vest 100% on the grant date, and are exercisable beginning that day until March 31, 2036. This is a compensation-related award rather than an open-market purchase or sale, and leaves Luput holding 28,556 stock options directly following the transaction.
MAIA Biotechnology, Inc. director Theagene Jean-Manasse received a grant of stock options covering 27,258 shares of common stock. The options have an exercise price of $1.40 per share, vest 100% on the grant date, and are exercisable immediately through March 31, 2036.
MAIA Biotechnology director Stan Smith reported an award of stock options as compensation. On March 31, 2026, an entity associated with him, The Stan V. Smith Trust Dated 1993, received 33,099 stock options under MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan.
The options give the right to buy an equal number of shares of common stock at an exercise price of $1.40 per share. They vest 100% on the grant date and are exercisable beginning that day, expiring on March 31, 2036. After this grant, the filing shows 33,099 options indirectly beneficially owned.
MAIA Biotechnology director Stan Smith reported indirect ownership changes in the company’s common stock. On September 19, 2022, The Stan V. Smith Trust Dated 1993, associated with him, purchased 2,700 shares of MAIA common stock at $3.6884 per share, bringing that trust’s reported indirect holdings to 1,424,178 shares.
On May 1, 2024, 20,000 shares previously held in the Stan V Smith CUST Gage Quentin Smith IL UNIF TRNS MIN Act account were transferred at $0 to The Stan V. Smith Trust Dated 1993, increasing that trust’s reported indirect holdings to 1,444,178 shares. Three additional IL Uniform Transfers to Minors Act accounts for family members each hold 4,580 shares, where Smith reports indirect beneficial ownership but disclaims it except to the extent of his pecuniary interest.
MAIA Biotechnology, Inc. reported that a company director received a new stock option grant. On 12/31/2025, the director was granted options to purchase 24,060 shares of MAIA Biotechnology common stock at an exercise price of $1.53 per share under the company’s 2021 Equity Incentive Plan. The options vest 100% on the grant date and are exercisable beginning on that date, with an expiration date of 12/31/2035. Following this grant, the director holds 24,060 derivative securities directly.
MAIA Biotechnology director option grant reported
MAIA Biotechnology, Inc. disclosed that director Stan V. Smith was granted stock options on 12/31/2025 under the company’s 2021 Equity Incentive Plan. The options cover 29,216 shares of common stock at an exercise price of $1.53 per share and vest 100% on the grant date, meaning they are exercisable beginning 12/31/2025.
The options have an expiration date of 12/31/2035. Following this grant, 29,216 derivative securities are shown as beneficially owned indirectly through The Stan V. Smith Trust Dated 1993.
MAIA Biotechnology director reports new stock option grant
A MAIA Biotechnology, Inc. director filed a Form 4 disclosing a grant of stock options on December 31, 2025 under the company’s 2021 Equity Incentive Plan. The grant covers 25,206 stock options, each giving the right to buy one share of MAIA common stock at an exercise price of $1.53 per share. These options vest 100% on the grant date and are exercisable beginning that same day, with an expiration date of December 31, 2035. Following this grant, the reporting person holds 25,206 derivative securities directly, all in the form of these options.
MAIA Biotechnology, Inc. reported that director Louie Ngar Yee received a grant of stock options on 12/31/2025 under the company’s 2021 Equity Incentive Plan. The grant covers 29,789 options to buy common stock at an exercise price of $1.53 per share.
The options vest 100% on the grant date and are exercisable beginning 12/31/2025, giving the director the right to purchase MAIA common shares at this fixed price. These options expire on 12/31/2035 if not exercised, so they represent a long-term equity incentive tied to the company’s future performance.
MAIA Biotechnology, Inc. reported an equity award to one of its directors. On December 31, 2025, the director received stock options to purchase 24,060 shares of MAIA common stock at an exercise price of $1.53 per share under the company’s 2021 Equity Incentive Plan. These options vest 100% on the grant date and are exercisable beginning on that date, with an expiration date of December 31, 2035. Following this grant, the director beneficially owns 24,060 derivative securities directly in the form of these options.
MAIA Biotechnology, Inc. reported an equity award to one of its directors on a Form 4 insider transaction report. On December 31, 2025, the director received 24,633 stock options under MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan. These options have an exercise price of $1.53 per share, vest 100% on the grant date, and are exercisable beginning December 31, 2025, through December 31, 2035. Following this grant, the director beneficially owns 24,633 derivative securities in the form of these options, held directly.
MAIA Biotechnology director Stan V. Smith reported buying additional shares and options in the company. On December 22, 2025, he purchased 57,189 shares of MAIA common stock at $1.224 per share under a Securities Purchase Agreement and the company’s 2021 Equity Incentive Plan. After this transaction, he beneficially owns 1,421,478 shares indirectly through The Stan V. Smith Trust Dated 1993, plus additional indirect holdings of 4,580 shares in each of three separate family trusts.
He also acquired 57,189 stock options (described as warrants deemed options) with an exercise price of $1.36 per share. These options become exercisable on the six-month anniversary of the issuance date, June 22, 2026, and expire three years after the initial issuance date, on December 22, 2028. The filing notes that certain family-trust shares are held for relatives and that he disclaims beneficial ownership of those except to the extent of any pecuniary interest.
MAIA Biotechnology director reports stock and option purchases. A company director filed details of a recent transaction in MAIA Biotechnology, Inc. common stock. On December 22, 2025, the director purchased 40,849 shares of common stock at a price of $1.224 per share under a Securities Purchase Agreement and the company’s 2021 Equity Incentive Plan. Following this transaction, the director beneficially owns 151,873 shares of MAIA common stock directly.
The director also acquired 40,849 stock options (treated as warrants under the same purchase agreement and plan) with an exercise price of $1.36 per share. These options become exercisable on June 22, 2026, which is six months after the issuance date, and are scheduled to expire on December 22, 2028.
MAIA Biotechnology, Inc. director Louie Ngar Yee reported an insider purchase of common stock and related stock options. On 12/22/2025, the director acquired 81,699 shares of common stock at $1.224 per share pursuant to a Securities Purchase Agreement, bringing total directly held common shares to 1,248,888.
On the same date, the director also acquired stock options on 81,699 shares with an exercise price of $1.36 per share. These options, deemed options under the company’s 2021 Equity Incentive Plan, become exercisable on 06/22/2026 and expire on 12/22/2028. Following these transactions, the director beneficially owns 81,699 derivative securities in addition to the common stock holdings.
MAIA Biotechnology, Inc. director Stan V. Smith reported open-market purchases of the company’s common stock. On December 5, 2025, three separate transactions were reported, each for 4,580 shares of MAIA common stock at prices of $1.1997, $1.19, and $1.20 per share, all coded as purchases. These shares are held indirectly through three Illinois Uniform Transfers to Minors Act accounts for Mr. Smith’s family members, and he reports beneficial ownership only to the extent of his pecuniary interest.
In addition, the filing shows 1,364,289 shares of MAIA common stock beneficially owned indirectly through The Stan V. Smith Trust dated 1993. The form is filed as a single-reporting-person filing and reflects Mr. Smith’s status as a director of MAIA Biotechnology.
MAIA Biotechnology, Inc. Chief Executive Officer and director Vlad Vitoc, a more than 10% owner of the company, reported an open-market purchase of common stock. On 11/25/2025, he bought 10,500 shares of MAIA common stock at a price of $0.9661 per share. Following this transaction, he directly owned 831,421 common shares and indirectly held 210,100 common shares through his spouse.
This filing is an amendment to a prior Form 4 originally filed on 11/28/2025. The amendment corrects the previously reported total share balance owned by Mr. Vitoc’s spouse and now reflects the correct indirect ownership amount, while also reiterating that he disclaims beneficial ownership of those spouse-held shares except to the extent of his economic interest.
MAIA Biotechnology’s chief executive officer, director and 10% owner Vlad Vitoc reported open‑market purchases of the company’s common stock and corrected prior share balances. On November 26, 2025, he bought 22,000 shares at a weighted average price of $1.0463 per share, and on November 28, 2025 he bought an additional 50,000 shares at a weighted average price of $1.1366 per share. Following these transactions, he directly owns 903,421 shares of MAIA common stock and has indirect beneficial ownership of 210,100 shares held by his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest. This Form 4 amendment corrects the previously reported total share balances for both his holdings and his spouse’s holdings.
MAIA Biotechnology (MAIA) insider Vlad Vitoc, the company’s Chief Executive Officer, director and a 10% owner, reported open-market purchases of MAIA common stock. On November 28, 2025, he bought 50,000 shares at a weighted average price of $1.1366 per share. On November 26, 2025, he bought an additional 22,000 shares at a weighted average price of $1.0463 per share.
After these transactions, Vitoc directly beneficially owns 881,421 shares of MAIA common stock and indirectly beneficially owns 210,000 shares through his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
MAIA Biotechnology, Inc. director Cristian Luput reported open-market purchases of the company’s common stock. On 11/26/2025, he bought 20,000 shares at a price of $1.0808 per share. On 11/28/2025, he purchased an additional 18,145 shares at a weighted average price of $1.1149 per share, with individual trades ranging from $1.1147 to $1.1192. After these transactions, he beneficially owned 437,628 shares of MAIA common stock, held directly.
MAIA Biotechnology director reports open-market stock purchase
Stan V. Smith, a director of MAIA Biotechnology, Inc., reported buying 15,000 shares of MAIA common stock on 11/26/2025. The purchase was made in the open market at a weighted average price of $1.0388 per share, with individual trades executed between $1.03 and $1.051. Following this transaction, Mr. Smith beneficially owned 1,364,289 shares of MAIA common stock, held indirectly through The Stan V. Smith Trust Dated 1993.
MAIA Biotechnology director reports open-market share purchase. A company director filed a Form 4 disclosing the acquisition of 10,000 shares of MAIA Biotechnology common stock on 11/25/2025. The shares were purchased at a price of $0.9785 per share. Following this transaction, the director beneficially owns 399,483 shares of MAIA common stock, held directly.
MAIA Biotechnology, Inc. reported an insider share purchase by its Chief Executive Officer, director and 10% owner Vlad Vitoc. On 11/25/2025, he bought 10,500 shares of common stock at a weighted average price of $0.9661 per share, with individual trades ranging from $0.9606 to $0.9745. After this transaction, he directly holds 831,421 common shares. An additional 210,000 shares are held by his spouse, which he reports as indirectly beneficially owned but disclaims ownership beyond his economic interest.
MAIA Biotechnology director reports insider share purchases. Director Stan V. Smith filed a Form 4 showing two open-market purchases of MAIA common stock. On 11/24/2025, he bought 10,000 shares at a weighted average price of $0.99, with individual trades ranging from $0.9675 to $0.9899. On 11/25/2025, he bought another 15,000 shares at a weighted average price of $0.98, with trades between $0.9550 and $1.05. Following these transactions, he beneficially owns 1,349,289 shares indirectly through The Stan V. Smith Trust Dated 1993.
MAIA Biotechnology CEO share purchases were reported by Vlad Vitoc, who serves as Chief Executive Officer, Director and 10% owner of MAIA Biotechnology, Inc. (MAIA). On 11/21/2025, he bought 1,800 shares of common stock at a weighted average price of $0.92 per share, and on 11/24/2025 he bought an additional 10,000 shares at a price of $0.9891 per share.
Following these transactions, Vitoc directly beneficially owned 820,921 shares of MAIA common stock. The filing also notes 210,100 shares beneficially owned by his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest. The weighted average disclosure indicates the 1,800-share purchase was executed in multiple trades within a narrow price range between $0.9128 and $0.9235.
MAIA Biotechnology reported a director stock-option grant disclosed on a Form 4. Stan V. Smith, a company director, received an award of 24,844 stock options on 10/02/2025 under the 2021 Equity Incentive Plan. The options have an exercise price of $1.80, vest 100% on the grant date, are exercisable immediately, and expire on 10/02/2035. The filing shows these shares are beneficially owned indirectly through The Stan V. Smith Trust Dated 1993, and the Form 4 was signed on 10/06/2025. The disclosure provides a clear record of insider compensation and ownership change but does not include company-wide share counts or percent ownership to measure dilution impact.
MAIA Biotechnology director Theagene Jean-Manasse received a grant of stock options for 20,459 shares on 10/02/2025. The options have an exercise price of $1.8, vest 100% on the grant date, are exercisable immediately, and expire on 10/02/2035. The filing shows the transaction was reported on 10/06/2025 and was filed as a Form 4 by one reporting person. The grant was made under the 2021 Equity Incentive Plan and represents a direct beneficial ownership of 20,459 shares via options.
Cristian Luput, a director of MAIA Biotechnology, Inc. (MAIA), reported a grant of stock options on 10/02/2025. The grant consists of 21,434 options under the company's 2021 Equity Incentive Plan that vest 100% on the grant date and are immediately exercisable. The options have an exercise price of $1.8 per share and expire on 10/02/2035.
The Form 4 was signed on 10/06/2025 and indicates the filing was submitted by one reporting person. The disclosure shows direct beneficial ownership of 21,434 shares following the transaction. No cash proceeds, sales, or other derivative transactions are reported in this filing.
MAIA Biotechnology, Inc. director Louie Ngar Yee reported a grant of 25,331 stock options on 10/02/2025. The options have an exercise price of $1.80, vest 100% immediately on the grant date, are exercisable immediately, and expire on 10/02/2035. The Form 4 indicates the filing was completed on 10/06/2025 and the reporting person is filing individually as a director. The grant was made under the company’s 2021 Equity Incentive Plan and represents a direct beneficial ownership of 25,331 shares upon exercise.
MAIA Biotechnology, Inc. director Ramiro Guerrero was granted 20,459 stock options on 10/02/2025 under the 2021 Equity Incentive Plan. The options are exercisable immediately and vest 100% on the grant date, giving the holder the right to buy 20,459 shares of common stock. The reported conversion/exercise price is $1.80 per share and the options expire on 10/02/2035. Following this transaction, the reporting person beneficially owns 20,459 derivative shares as disclosed on the Form 4.
MAIA Biotechnology director Steven M. Chaouki received a grant of 20,946 stock options under the 2021 Equity Incentive Plan. The options are exercisable immediately, vesting 100% on grant, and carry an exercise price of $1.8 per share. The award represents a direct ownership interest of 20,946 shares underlying common stock following the transaction. The options expire ten years from grant and were reported on the required Form 4 filing.
This action increases the director's potential economic exposure to the company’s common stock and creates a near-term option position that could be exercised to acquire shares at the stated exercise price.